Peptides used for weight loss work primarily by mimicking gut hormones that control hunger, blood sugar, and how quickly food moves through your digestive system. The most effective versions, available as once-weekly injections, have produced average weight loss of 13% to 29% of body weight in clinical trials. These aren’t fringe supplements. The leading peptide-based medications target specific receptors in your brain and gut to fundamentally shift how much you want to eat and how your body processes energy.
The Hormones Behind the Weight Loss
Your intestines naturally release hormones called GLP-1 and GIP after you eat. These hormones signal your brain to feel full, tell your pancreas to release insulin, and slow digestion so nutrients absorb gradually. Peptide weight loss medications are lab-made versions of these hormones, engineered to last much longer in the body than the natural versions, which break down within minutes.
GLP-1 works in two key areas of the brain that regulate appetite and nausea. It reduces how much food you want to eat by enhancing feelings of fullness during a meal, effectively shrinking your portion sizes without the white-knuckle willpower of traditional dieting. GIP adds to that appetite suppression while also calming the nausea circuits that GLP-1 can trigger. This is why newer medications that target both hormones tend to produce more weight loss with fewer stomach-related side effects than older ones targeting GLP-1 alone.
Beyond appetite, these peptides slow gastric emptying, meaning food sits in your stomach longer. This extends the physical sensation of fullness between meals. They also improve insulin sensitivity and help your body store dietary fats more efficiently in fat tissue rather than letting lipids accumulate in places like the liver, where they cause metabolic damage.
How Much Weight People Actually Lose
The numbers vary depending on which peptide you’re using. In the head-to-head SURMOUNT-5 trial, people on tirzepatide (which targets both GLP-1 and GIP receptors) lost an average of 20.2% of their body weight, about 50 pounds, over the study period. Those on semaglutide (targeting GLP-1 only) lost 13.7%, roughly 33 pounds. That’s a 47% greater weight loss with the dual-targeting approach.
A next-generation peptide called retatrutide, which targets three receptors (GLP-1, GIP, and glucagon), has shown even more dramatic results. In its Phase 3 trial, participants on the highest dose lost an average of 28.7% of their body weight, about 71 pounds, over 68 weeks. For context, the placebo group lost just 2.1%. Retatrutide is not yet FDA-approved but is in late-stage trials.
What Happens to Muscle During Weight Loss
One common concern is whether these medications cause you to lose muscle along with fat. Early data suggested that roughly 40% of the weight lost on semaglutide came from lean body mass rather than fat, which is higher than the typical 25% seen with conventional dieting. That number raised alarm.
More recent research paints a more reassuring picture. A 2026 study published in Cell Reports Medicine found that in both mice and humans, the weight loss from GLP-1 medications is primarily driven by fat loss. In animal models, semaglutide reduced body fat by about 51% while lean mass dropped only around 5%. The study found that even though lean mass decreased in absolute terms, the ratio of muscle to total body weight actually improved. In practical terms, you end up lighter and leaner, not weaker, though adding resistance exercise during treatment is a straightforward way to preserve more muscle.
What’s FDA-Approved Right Now
Two peptide-based medications are currently FDA-approved specifically for chronic weight management: semaglutide (sold as Wegovy) and tirzepatide (sold as Zepbound). Both are prescribed for adults with a BMI of 30 or higher, or 27 or higher if they also have a weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. Both are meant to be used alongside dietary changes and exercise.
Zepbound is administered as a once-weekly injection under the skin. The dose starts low and gradually increases over 4 to 20 weeks, reaching a target of 5, 10, or 15 milligrams weekly. Semaglutide follows a similar slow ramp-up, typically starting at 0.25 milligrams weekly and increasing over about 16 weeks to a maintenance dose of 2.4 milligrams. The gradual increase exists specifically to let your body adjust and reduce side effects.
Side Effects to Expect
Gastrointestinal issues are the most common side effects by a wide margin. Nausea, constipation, diarrhea, bloating, heartburn, and vomiting all appear frequently, especially during the dose-escalation period when your body is adjusting. For most people, these symptoms ease as they settle into their maintenance dose. The slow titration schedule is designed to minimize this transition period, which is why skipping ahead to higher doses creates problems.
There is a regulatory warning against using GLP-1 medications if you have a personal or family history of medullary thyroid cancer or a condition called multiple endocrine neoplasia type 2. This stems from rodent studies that showed an increase in thyroid tumors at high doses. Recent research suggests the association in humans may reflect detection bias rather than true causation, but the FDA warning remains in place.
Benefits Beyond the Scale
The cardiovascular effects of these medications are significant and go beyond what you’d expect from weight loss alone. GLP-1 medications as a class have been shown to improve blood pressure and reduce rates of heart attack, stroke, and cardiovascular death. Tirzepatide appears to push these benefits further. An observational study published in JACC: Advances found that people on tirzepatide had a 40% lower rate of a combined outcome of heart attack, stroke, and death compared to those on GLP-1-only medications. New-onset atrial fibrillation was 77% lower in the tirzepatide group, and heart failure exacerbations dropped by 40%.
Compounded Peptides Carry Real Risks
The high cost of brand-name medications has driven many people toward compounded versions of semaglutide and tirzepatide, purchased from compounding pharmacies or online sellers. The FDA has flagged serious concerns with these products. Compounded drugs are not reviewed for safety, effectiveness, or quality before they’re sold. As of July 2025, the FDA has received 605 adverse event reports linked to compounded semaglutide and 545 linked to compounded tirzepatide.
The problems are varied and concrete. Some compounded injectables have arrived without proper refrigeration, which degrades the medication. Dosing errors have led to hospitalizations, caused by patients measuring incorrect amounts or healthcare providers miscalculating concentrations. Some products contain salt forms of semaglutide (like semaglutide sodium or semaglutide acetate) that are chemically different from the FDA-approved version, with unknown safety profiles. The FDA has also identified outright fraudulent products with fake pharmacy names on the labels.
Compounded versions of retatrutide and cagrilintide (another peptide in development) cannot legally be used in compounding under federal law, since they are not components of any approved drug. If you see them for sale, they exist entirely outside the regulatory system.